Inoten Tablet

About Inoten 20 mg Tablet

Inoten is a 20 mg tablet made by Opsonin Pharma Limited. It contains tenoxicam, a non-steroidal anti-inflammatory medicine used for painful inflammatory and degenerative joint and muscle conditions.

There are 5 brands of Tenoxicam listed in Bangladesh. 3 of them have a lower unit price than Inoten.

What is Inoten 20 mg Tablet?

Inoten 20 mg tablet is manufactured by Opsonin Pharma Limited. Its active ingredient is tenoxicam, which belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It is prescribed for the symptomatic treatment of painful inflammatory and degenerative disorders of the musculoskeletal system. It comes as a tablet in a 3 x 10 pack. The doctor decides the dose and course of treatment for each patient.

Uses of Inoten

Inoten is used for the symptomatic treatment of painful inflammatory and degenerative disorders of the musculoskeletal system. These include rheumatoid arthritis, osteoarthritis, arthrosis, ankylosing spondylitis, and extra-articular disorders such as tendinitis, bursitis, periarthritis of the shoulders or hips, strains and sprains. It is also used for acute gout. The doctor decides whether it suits a particular patient.

How to use Inoten

Take Inoten exactly as the doctor or pharmacist advises. The dose and course are chosen by the doctor for each patient and are not fixed for everyone. Swallow the tablet with water. Do not start, stop or change the medicine on your own. If you miss a dose or are unsure how to take it, ask your doctor or pharmacist for guidance.

Side effects of Inoten

Inoten is generally tolerated at the recommended dose, and unwanted effects are usually mild and short-lived. Reported effects include stomach and upper abdominal discomfort, indigestion, heartburn and nausea, as well as dizziness and headache. Constipation has also been reported less often. Tell your doctor if any effect bothers you or does not settle. Ask your doctor or pharmacist about anything you notice while taking it.

Safety and precautions

Do not take Inoten if you are hypersensitive to it, if salicylates or other NSAIDs cause you asthma, rhinitis or urticaria, or if you have or have had upper gastrointestinal disease such as gastritis, gastric or duodenal ulcer. Treatment during the third trimester of pregnancy should be avoided, and breastfeeding mothers should ask their doctor. People with kidney, liver or heart conditions, or who take other medicines, should speak to the doctor before use.

Frequently asked questions

What is the price of Inoten 20 mg tablet?

The listed price is ৳ 8.03. Prices can change, so check with your pharmacy or the site listing for the current price before buying.

How should I store Inoten 20 mg tablet?

Do not store it above 30°C, and protect it from light and moisture. Keep it out of the reach of children. Ask your pharmacist if you are unsure how to store it properly.

What is Inoten used for and what kind of medicine is it?

Inoten is a non-steroidal anti-inflammatory drug (NSAID) containing tenoxicam. It is used for symptomatic treatment of painful inflammatory and degenerative musculoskeletal disorders, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, strains, sprains and acute gout.

Which medicines may interact with Inoten?

Concurrent use with salicylates or other NSAIDs should be avoided because of a higher risk of gastrointestinal problems. Caution is advised with methotrexate. Tell your doctor or pharmacist about all medicines you take, including those bought without a prescription.

Indications

Tenoxicam is indicated for the symptomatic treatment of the following painful inflammatory and degenerative disorders of the musculoskeletal system:
  • Rheumatoid arthritis.
  • Osteoarthritis.
  • Arthrosis.
  • Ankylosing spondylitis.
  • Extra-articular disorders, e.g. tendinitis, bursitis, periarthritis of the shoulders (shoulder-hand syndrome) or hips, strains, and sprains.
  • Acute gout.

Pharmacology

Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties and it also inhibits platelet aggregation. Tenoxicam inhibits prostaglandin biosynthesis. In-vitro tests of leukocyte peroxidase suggest that tenoxicam may act as a scavenger for active oxygen at the site of inflammation. Tenoxicam is a potent in-vitro inhibitor of human metalloproteinases (stromelysin and collagenase), which induce cartilage breakdown. These pharmacological effects explain, at least in part, the therapeutic benefit of Tenoxicam in the treatment of painful inflammatory and degenerative disorders of the musculoskeletal system. Tenoxicam showed no mutagenic, carcinogenic or teratogenic effects in animals. As with other prostaglandin inhibitors, renal and gastrointestinal effects, increased incidence of dystocia and delayed parturition were observed in animal safety studies.

Dosage & Administration

Standard dosage: For all indications except acute gout, a daily dosage of 20 mg should be given at the same time of day.

In acute attacks of gout: The recommended dose for acute attacks of gout is 40 mg once daily for two days followed by 20 mg once daily for a further five days.

In the treatment of chronic disorders: The therapeutic effect of tenoxicam is evident early in treatment but there is a progressive increase in response over time. In chronic disorders, daily doses higher than 20 mg should be avoided since this would increase the frequency and intensity of unwanted reactions without significantly increasing efficacy. For patients needing long-term treatment, a reduction to a daily oral dose of 10 mg may be tried for maintenance.

Special dosage instructions: In principle, the above dosage recommendations also apply to elderly patients and to patients suffering from kidney or liver disease. Because of lack of clinical experience, no dosage recommendations have so far been established for children and adolescents.

Interaction

As in the case of other NSAIDs, salicylate displaces tenoxicam from protein-binding sites and increases clearance and volume of distribution of tenoxicam. Concurrent treatment with salicylate or other NSAIDs should be avoided because of increased risk of gastrointestinal undesirable reactions. The co-administration of some NSAIDs and methotrexate has been associated with reduced renal tubular secretion of methotrexate, higher plasma concentrations of methotrexate, and severe methotrexate toxicity. Therefore, caution should be exercised when Tenoxicam is administered concurrently with methotrexate. No clinically relevant interaction was found in the small number of patients receiving concomitant treatment with gold, penicillamine or probenecid. As Tenoxicam may decrease the renal clearance of lithium, their concomitant administration may lead to increased plasma levels and toxicity of lithium. The plasma levels of lithium should be closely monitored. As with NSAIDs in general, Tenoxicam should not be administered concurrently with K-sparing diuretics. There is a known interaction between these two classes of compounds, which may cause hyperkalemia and renal failure. No clinically significant interaction between Tenoxicam and furosemide was noted, but Tenoxicam attenuates the blood pressure-lowering effect of hydrochlorothiazide. As known from other NSAIDs, Tenoxicam might attenuate the antihypertensive effects of alpha-adrenergic blockers and ACE-inhibitors. No interactions have been reported between NSAIDs and centrally-acting alpha agonists or calcium channel blockers. There was no clinically relevant interaction when Tenoxicam was administered together with atenolol. During clinical trials no interaction was reported for patients treated concomitantly with digitalis products. Thus concurrent dosing of Tenoxicam and digoxin appears to be without major risk. No interaction has been found with concomitantly administered antacids, cimetidine, warfarin and phenprocoumon at the recommended dosages. The clinical effect of oral antidiabetic drugs (glibornuride, glibenclamide, tolbutamide) was likewise not modified by Tenoxicam. Nevertheless, careful monitoring is recommended when patients concomitantly receive anticoagulants or oral antidiabetic drugs. No clinically relevant interaction has been found between Tenoxicam and low molecular weight heparin.

Contraindications

Tenoxicam must not be administered to patients:
  • known to be hypersensitive to the drug;
  • in whom salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs) induce symptoms of asthma, rhinitis, or urticaria;
  • suffering or having suffered from the disease of the upper gastrointestinal tract, such as gastritis, gastric and duodenal ulcer.

Side Effects

Based on clinical trials including large numbers of patients, Tenoxicam proved to be well tolerated in the recommended dose. Usually, the undesirable effects reported were mild and transient. In a small proportion of patients, the interruption of treatment due to undesirable effects was necessary. Local tolerance of Tenoxicam given parenterally was good. The following undesirable effects have been reported:

Frequency is greater than 1%-
  • Gastrointestinal tract: gastric, epigastric and abdominal discomfort, dyspepsia, heartburn, nausea.
  • Central nervous system: dizziness, headache.
Frequency less than 1%-
  • Gastrointestinal tract: constipation, diarrhea, stomatitis, gastritis, vomiting, ulcers, Gl-bleeding including hematemesis and melena.
  • Central nervous system: fatigue, sleep disturbances, appetite loss, dry mouth, vertigo.
  • Skin: itching (also in the anal region after rectal administration), erythema, exanthema, rash, urticaria.
  • Urinary tract and kidneys: increase in BUN or creatinine, edema.
  • Liver and biliary tract: increased liver enzyme activity.
  • Cardiovascular system: palpitations.
Isolated cases (frequency less than 0.01%)-
  • Gastrointestinal tract: Gl-perforation.
  • Central nervous system: visual disturbances.
  • Skin: Stevens-Johnson and Lyell's syndrome, photosensitivity reaction, vasculitis.
  • Blood: anemia, agranulocytosis, leukopenia, thrombocytopenia.
  • Hypersensitivity reactions: dyspnea, asthma, anaphylaxis, angioedema.
  • Cardiovascular system: elevated blood pressure, mainly in patients treated with cardiovascular drugs.
  • Liver/Biliary tract: hepatitis.

Pregnancy & Lactation

NSAIDs have an inhibitory effect on prostaglandin synthesis and, when given during late pregnancy, may cause the closure of the fetal ductus arteriosus, prolong labor and delay parturition. Treatment during the third trimester of pregnancy should be avoided. Based on findings from single-dose administration, a very small amount (approximately 0.2%) of tenoxicam passes into breast milk. There is no evidence of adverse reactions in breast-fed infants of mothers taking Tenoxicam. Nevertheless, infants should be weaned or the drug discontinued.

Precautions & Warnings

NSAIDs inhibit renal prostaglandin synthesis and consequently may have an undesirable effect on renal hemodynamics and on salt and water balance. It is necessary to adequately monitor the patient with a special emphasis on cardiac and renal function (BUN, creatinine, development of edema, weight gain, etc.) when giving Tenoxicam to patients with conditions that could increase their risk of developing renal failure, such as pre-existing renal disease, impaired renal function in diabetics, hepatic cirrhosis, congestive heart failure, volume depletion or concomitant treatment with potentially nephrotoxic drugs, diuretics and corticosteroids. Tenoxicam inhibits platelet aggregation and may affect hemostasis. Tenoxicam has no significant influence on blood coagulation factors, coagulation time, prothrombin time or activated thromboplastin time. Patients having coagulation disorders or receiving drug therapy that interferes with hemostasis should, however, be carefully observed when Tenoxicam is administered. Any patient being treated with Tenoxicam who presents with symptoms of gastrointestinal disease should be closely monitored. If peptic ulceration or gastrointestinal bleeding occurs, Tenoxicam should be immediately withdrawn. If severe skin reactions (e.g. Lyell's or Stevens-Johnson syndrome) occur, the treatment should be discontinued immediately. Adverse eye findings have been reported with Tenoxicam. Thus ophthalmic evaluation is recommended for patients who develop visual disturbances. Because of the high plasma protein binding of tenoxicam, caution is required when plasma albumin levels are markedly reduced. In common with anti-inflammatory drugs, Tenoxicam may mask the usual signs of infection. Tenoxicam Tablets should not be given to patients who either dislike or do not tolerate milk products.

Overdose Effects

Although there is no experience of acute overdosage with Tenoxicam, it may be expected that the signs and symptoms mentioned under Undesirable effects would be more pronounced. Overdose should be countered by conventional measures to reduce absorption (e.g. gastrolavage and charcoal) and speed up elimination (e.g. cholestyramine).

Storage Conditions

Do not store above 30°C, protect from light & moisture. Keep out of the reach of children.

Alternative brands of Tenoxicam

Other brands with the same generic name, cheapest first.

Enocam Tablet

20 mg

Tenoxicam

The ACME Laboratories Ltd.

৳ 7.87 ৳ 8.03 2% off per unit

Tenorix Tablet

20 mg

Tenoxicam

Orion Pharma Ltd.

৳ 7.9 ৳ 8.06 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.